REG - Indivior PLC - Indivior to Participate in Conference

IndiviorAnnouncement

21/02/2023 12:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230221:nRSU5986Qa&default-theme=true

RNS Number : 5986Q  Indivior PLC  21 February 2023

 

 

Indivior to Participate in Upcoming Credit Suisse 2023 Global Healthcare
Conference

 

Slough, UK, and Richmond, VA, February 21, 2023 - Indivior PLC (LSE: INDV)
today announced that Mark Crossley, Chief Executive Officer, and Ryan
Preblick, Chief Financial Officer, will participate in the Credit Suisse 2023
Global Healthcare Conference in London.  Mr. Crossley and Mr. Preblick will
host 1:1 and group meetings February 28(th).

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat substance use disorders (SUD) and
serious mental illnesses. Our vision is that all patients around the world
will have access to evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from
a global human crisis to a recognized and treated chronic disease. Building on
its global portfolio of OUD treatments, Indivior has a pipeline of product
candidates designed to both expand on its heritage in this category and
potentially address other chronic conditions and co-occurring disorders of
SUD, including alcohol use disorder and cannabis use disorder. Headquartered
in the United States in Richmond, VA, Indivior employs more than 900
individuals globally and its portfolio of products is available in 39
countries worldwide. Visit www.indivior.com
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.indivior.com%2F&data=04%7C01%7Cjason.thompson%40Indivior.com%7C50524c1bfa284722f7ee08da13118474%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C637843263192018647%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=XV57BWLOjOnGhAQJWI0WKEK4%2FXf0M9QcOEiYwwerqho%3D&reserved=0)
to learn more. Connect with Indivior on LinkedIn by visiting
www.linkedin.com/company/indivior
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Findivior&data=04%7C01%7Cjason.thompson%40Indivior.com%7C50524c1bfa284722f7ee08da13118474%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C637843263192018647%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=ztGNJPoRRJvCmxgR2tqSP1oJuDdNpAGH7hPFUtuOHcA%3D&reserved=0)
.

 

 

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: +1 804 402 7123 or jason.thompson@indivior.com
(mailto:jason.thompson@indivior.com)

 

Tim Owens

Director, Investor Relations

Tel: +1 804 263 3978 or timothy.owens@indivior.com
(mailto:timothy.owens@indivior.com)

 

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAAAFAFLDEFA